We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Pathogenic Yeasts Quantified by Flow Cytometry

By LabMedica International staff writers
Posted on 12 Feb 2013
A flow cytometric, single-stain approach to quantify Candida albicans has been investigated as an alternative to the standard viable plate count.

In clinical settings, viable plate counts (VPC) are used to determine the patient's microbial load, but it is labor intensive, time consuming, and only allows detection of those organisms that readily grow on solid media.

Microbiologists at the University of Antwerp (Belgium) investigated a single-stain, flow cytometric approach for the enumeration of viable C. More...
albicans cells. This single-stain strategy is based on the differences in the fluorescence intensity between viable and nonviable cells. In this study, the cells with an intact membrane are considered alive, while the cells with a damaged membrane are defined as dead.

Cell samples were stained with TO-PRO-3 iodide (TP3; Molecular Probes, OR, USA) which has a peak excitation at 642 nm with emission at 661 nm. All flow cytometry (FCM) studies were performed using a FACSCalibur flow cytometer (BD Biosciences, NJ, USA) equipped with a red diode laser (excitation at 633 nm) and a band pass filter measuring red fluorescence (FL4; range 653–669 nm). Molecular Probes' CountBright absolute counting beads were added to the samples as an internal standard to calculate the exact volume analyzed by the flow cytometer.

The authors concluded that the FCM quantification of viable cells using TP3 is a good alternative for the more time consuming and labor-intensive VPC. In comparison to other FCM techniques, this single-stain procedure is simple to apply and cost-effective since only one dye needs to be added. Moreover, the unique excitation/emission profile of TP3 allows the application of additional dyes to assess other cellular parameters with minimal spectral overlap. The study is planned for publication in print on February 15, 2013, in the Journal of Microbiological Methods.

Related Links:

University of Antwerp
Molecular Probes
BD Biosciences




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.